{"id":"physician-s-choice-medications","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108889","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Physician's Choice medications allow healthcare providers to select the most appropriate treatment option for a patient based on their individual needs and medical history. This approach can lead to better patient outcomes and improved quality of care.","oneSentence":"Physician's Choice medications are a class of treatments that provide a choice between different medications for a specific condition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:10.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple Indications"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT07391774","phase":"PHASE3","title":"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-07","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8","enrollment":1978},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT06926868","phase":"PHASE2, PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":"Breast Neoplasms","enrollment":500},{"nctId":"NCT04008797","phase":"PHASE1, PHASE2","title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-07-11","conditions":"Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular","enrollment":301},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis","enrollment":184},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT07466498","phase":"PHASE2","title":"Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-08-01","conditions":"Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":60},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT07044336","phase":"PHASE3","title":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-01","conditions":"Endometrial Cancer, Malignant Solid Tumour","enrollment":700},{"nctId":"NCT06551324","phase":"PHASE3","title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-10-21","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":600},{"nctId":"NCT07432373","phase":"","title":"Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection","status":"NOT_YET_RECRUITING","sponsor":"National University of Malaysia","startDate":"2026-04-01","conditions":"Pleural Infection","enrollment":80},{"nctId":"NCT06203210","phase":"PHASE3","title":"A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-05-21","conditions":"Small Cell Lung Cancer","enrollment":540},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT06346067","phase":"PHASE3","title":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2024-04-29","conditions":"Advanced or Metastatic NRAS-mutant Melanoma","enrollment":78},{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":399},{"nctId":"NCT05903417","phase":"NA","title":"Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2023-07-10","conditions":"Pleural Infection","enrollment":40},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT04947254","phase":"PHASE2","title":"Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-05","conditions":"Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":200},{"nctId":"NCT06595563","phase":"PHASE2","title":"HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2026-02","conditions":"HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer","enrollment":87},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":"Solid Tumors, Lymphoma","enrollment":40},{"nctId":"NCT04972721","phase":"","title":"SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-01","conditions":"Overweight, Obesity","enrollment":3439},{"nctId":"NCT04639986","phase":"PHASE3","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2020-11-23","conditions":"Metastatic Breast Cancer","enrollment":331},{"nctId":"NCT07382375","phase":"NA","title":"AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Medical University","startDate":"2027-12-31","conditions":"Aortic Aneurysm and Dissection","enrollment":300},{"nctId":"NCT05832762","phase":"NA","title":"Evaluation of Acute Endovascular Treatment in Symptomatic Isolated Cervical Internal Carotid Artery Occlusion (ETICA)","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2024-08-19","conditions":"Acute Ischemic Stroke","enrollment":200},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT07351591","phase":"PHASE2","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2026-01-30","conditions":"Advanced Biliary Tract Cancer(BTC)","enrollment":88},{"nctId":"NCT07351513","phase":"PHASE2","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2026-01-30","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":94},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT07255404","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-12-04","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":105},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT03896620","phase":"","title":"Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2019-06-18","conditions":"Sarcoma","enrollment":50},{"nctId":"NCT03879447","phase":"","title":"Effectiveness and Safety of Korean Medicine for Low Back Pain or Sciatica Due to Lumbar Stenosis/Spondylolisthesis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaseng Medical Foundation","startDate":"2019-06-24","conditions":"Lumbar Spinal Stenosis, Lumbar Spondylolisthesis, Low Back Pain","enrollment":110},{"nctId":"NCT03959098","phase":"","title":"Effectiveness and Safety of Korean Medicine Treatment for Cervical Disc Herniation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaseng Medical Foundation","startDate":"2019-06-24","conditions":"Neck Pain, Cervical Radiculopathy, Intervertebral Disc Displacement","enrollment":120},{"nctId":"NCT07087860","phase":"PHASE2","title":"Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-01","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":70},{"nctId":"NCT07262437","phase":"NA","title":"Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Milan","startDate":"2025-11-15","conditions":"Uveitis Posterior Non-Infectious, Inflammation Eye, Uveitis","enrollment":220},{"nctId":"NCT06742931","phase":"NA","title":"Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-04-07","conditions":"Chronic Coronary Syndrome","enrollment":1200},{"nctId":"NCT07251062","phase":"PHASE2, PHASE3","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-12-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":737},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":"Metastatic Breast Cancer","enrollment":1017},{"nctId":"NCT03734029","phase":"PHASE3","title":"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":557},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT06079983","phase":"PHASE3","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT06624644","phase":"PHASE2, PHASE3","title":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","status":"RECRUITING","sponsor":"Linnaeus Therapeutics, Inc.","startDate":"2025-08-06","conditions":"Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma","enrollment":135},{"nctId":"NCT07156058","phase":"NA","title":"MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-01-01","conditions":"Biliary Tract Cancer","enrollment":204},{"nctId":"NCT07148544","phase":"NA","title":"The Effect of the Sedo-Analgesia Protocol Applied to Intensive Care Unit Patients on Patient Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cukurova University","startDate":"2025-07-01","conditions":"Neurosurgical Surgery, Sedo-analgesia, İntensive Care","enrollment":42},{"nctId":"NCT04680988","phase":"PHASE2","title":"A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-05","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":194},{"nctId":"NCT06772233","phase":"PHASE2","title":"A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-07-30","conditions":"Metastatic Gastrointestinal Stromal Tumors (GIST)","enrollment":100},{"nctId":"NCT05300958","phase":"PHASE2","title":"Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2022-03-21","conditions":"Triple Negative Breast Cancer","enrollment":25},{"nctId":"NCT04473911","phase":"PHASE1","title":"Haplo Peripheral Blood Sct In GVHD Prevention","status":"COMPLETED","sponsor":"Zachariah Michael DeFilipp","startDate":"2020-08-14","conditions":"GVHD, AML, ALL","enrollment":25},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT06602063","phase":"PHASE1, PHASE2","title":"Surgery for Relapsed Ovarian Cancer in Precision","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Gynecologic Oncology Group","startDate":"2025-07","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":33},{"nctId":"NCT06954246","phase":"PHASE3","title":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06-04","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":450},{"nctId":"NCT04188548","phase":"PHASE1","title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-12-10","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT06592222","phase":"","title":"A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-08-26","conditions":"Multiple Myeloma","enrollment":4},{"nctId":"NCT06138990","phase":"PHASE2","title":"Pharmacoscopy-guided Clinical Standard-of-care in r/r AML","status":"RECRUITING","sponsor":"ETH Zurich","startDate":"2024-09-02","conditions":"AML, Adult","enrollment":88},{"nctId":"NCT06917092","phase":"PHASE2","title":"QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-05-01","conditions":"Endometrial Adenocarcinoma, Endometrial Cancer","enrollment":30},{"nctId":"NCT04364048","phase":"PHASE2","title":"Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Rachel Sanborn","startDate":"2020-06-18","conditions":"Lung Cancer, Non-small Cell Carcinoma","enrollment":10},{"nctId":"NCT06143553","phase":"PHASE3","title":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2023-09-25","conditions":"Metastatic Breast Cancer (MBC)","enrollment":168},{"nctId":"NCT06102824","phase":"PHASE2","title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-10-01","conditions":"HER2-negative Breast Cancer, Advanced Breast Cancer","enrollment":252},{"nctId":"NCT06692166","phase":"PHASE3","title":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2024-09-10","conditions":"Cervical Cancer","enrollment":420},{"nctId":"NCT04701476","phase":"PHASE2","title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","status":"RECRUITING","sponsor":"Teclison Ltd.","startDate":"2021-05-20","conditions":"Colorectal Cancer; Lung Cancer","enrollment":110},{"nctId":"NCT05684731","phase":"PHASE1","title":"Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-02-01","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT04647292","phase":"PHASE2","title":"European Blood Pressure Intensive Control After Stroke","status":"RECRUITING","sponsor":"University College Dublin","startDate":"2024-05-02","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":142},{"nctId":"NCT03874897","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.","status":"COMPLETED","sponsor":"Peking University","startDate":"2019-03-26","conditions":"Advanced Solid Tumor","enrollment":134},{"nctId":"NCT02448420","phase":"PHASE2","title":"Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2015-07","conditions":"Metastatic Breast Cancer","enrollment":73},{"nctId":"NCT06341621","phase":"PHASE3","title":"Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-02","conditions":"Breast Cancer","enrollment":1900},{"nctId":"NCT04470947","phase":"","title":"Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2020-06-10","conditions":"Advanced Lymphoma, Refractory Lymphoma, Refractory Leukemia","enrollment":150},{"nctId":"NCT04566939","phase":"","title":"A Long Term Follow-Up of Rotator Cuff Tear Patients Treated With Integrated Complementary and Alternative Medicine","status":"COMPLETED","sponsor":"Jaseng Medical Foundation","startDate":"2020-09-21","conditions":"Rotator Cuff Tear","enrollment":168},{"nctId":"NCT06268652","phase":"PHASE3","title":"Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-15","conditions":"Breast Cancer, Refractory Breast Carcinoma","enrollment":302},{"nctId":"NCT04400695","phase":"PHASE3","title":"A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2020-09-29","conditions":"Breast Cancer","enrollment":366},{"nctId":"NCT04714190","phase":"PHASE3","title":"A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2021-03-24","conditions":"Gastric Cancer, HER2 Overexpressing Gastric Carcinoma","enrollment":351},{"nctId":"NCT05310799","phase":"NA","title":"Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed JIA","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2023-05-23","conditions":"Juvenile Idiopathic Arthritis","enrollment":842},{"nctId":"NCT03262935","phase":"PHASE3","title":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Byondis B.V.","startDate":"2017-12-15","conditions":"Metastatic Breast Cancer","enrollment":437},{"nctId":"NCT01091038","phase":"PHASE2, PHASE3","title":"Improving Safety by Basic Computerizing Outpatient Prescribing","status":"COMPLETED","sponsor":"Indiana University","startDate":"2001-08","conditions":"Adverse Drug Events","enrollment":228},{"nctId":"NCT02257723","phase":"","title":"The Effect of Integrated CAM Treatment in Hospitalized Patients","status":"RECRUITING","sponsor":"Jaseng Hospital of Korean Medicine","startDate":"2012-01","conditions":"Low Back Pain, Neck Pain, Knee Pain","enrollment":100000},{"nctId":"NCT04446416","phase":"NA","title":"Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients","status":"COMPLETED","sponsor":"NaviFUS Corporation","startDate":"2020-07-21","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":6},{"nctId":"NCT05982223","phase":"NA","title":"Integrative Medicine in Lymphoma Survivors","status":"RECRUITING","sponsor":"Bnai Zion Medical Center","startDate":"2023-07-13","conditions":"Lymphoma","enrollment":90},{"nctId":"NCT03786406","phase":"","title":"An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-12-03","conditions":"Diabetes Mellitus, Type 2","enrollment":2275},{"nctId":"NCT05003726","phase":"NA","title":"Non-pharmacological Treatment and Pharmacological Treatment for Non-acute Lumbar Disc Herniation","status":"COMPLETED","sponsor":"Jaseng Hospital of Korean Medicine","startDate":"2021-10-15","conditions":"Lumbar Disc Herniation, Radiculopathy Lumbar","enrollment":36},{"nctId":"NCT03613181","phase":"PHASE3","title":"ANG1005 in Leptomeningeal Disease From Breast Cancer","status":"UNKNOWN","sponsor":"Angiochem Inc","startDate":"2023-12","conditions":"Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases","enrollment":150},{"nctId":"NCT03888287","phase":"NA","title":"Parkinson's Disease Inpatient Clinical Knowledge and Management","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2018-08-01","conditions":"Parkinson Disease","enrollment":477},{"nctId":"NCT03772353","phase":"PHASE1, PHASE2","title":"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-05-12","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT05255107","phase":"PHASE2, PHASE3","title":"Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers","status":"UNKNOWN","sponsor":"Peschke GmbH","startDate":"2022-03-14","conditions":"Keratitis, Corneal Ulcer","enrollment":468},{"nctId":"NCT04833270","phase":"NA","title":"Pragmatic Randomized Controlled Trial of Non-pharmacological Treatment for Lumbar Disc Herniation : A Pilot Study","status":"COMPLETED","sponsor":"Jaseng Hospital of Korean Medicine","startDate":"2021-07-09","conditions":"Lumbar Disc Prolapse With Radiculopathy","enrollment":30},{"nctId":"NCT04173923","phase":"","title":"Long Term Follow-up of Cervical Myelopathy Inpatients Treated With Integrated Complementary and Alternative Medicine","status":"COMPLETED","sponsor":"Jaseng Medical Foundation","startDate":"2018-11-20","conditions":"Cervical Myelopathy","enrollment":40},{"nctId":"NCT02841163","phase":"","title":"Disc Resorption in Lumbar and Cervical Disc Herniation Patients Receiving Integrative Korean Medicine Treatment","status":"COMPLETED","sponsor":"Jaseng Medical Foundation","startDate":"2016-04","conditions":"Lumbar Intervertebral Disc Displacement, Cervical Intervertebral Disc Displacement","enrollment":505},{"nctId":"NCT05444998","phase":"PHASE2","title":"Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-11-01","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT04676243","phase":"PHASE3","title":"Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML","status":"WITHDRAWN","sponsor":"University Hospital Heidelberg","startDate":"2022-05","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT04745975","phase":"PHASE2","title":"Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-02-01","conditions":"Triple Negative Breast Cancer","enrollment":100},{"nctId":"NCT03329690","phase":"PHASE2","title":"DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2017-11-02","conditions":"Neoplasm, Gastrointestinal","enrollment":233}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["corticosteroids","hydroxyurea","danazol","low-dose ruxolitinib"],"phase":"phase_3","status":"active","brandName":"Physician's Choice medications","genericName":"Physician's Choice medications","companyName":"Swedish Orphan Biovitrum","companyId":"swedish-orphan-biovitrum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Physician's Choice medications are a class of treatments that provide a choice between different medications for a specific condition. Used for Multiple Indications.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}